These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 35940211)

  • 1. Long-term outcomes of type 1 retinopathy of prematurity following monotherapy with bevacizumab: a Canadian experience.
    Isaac M; Mireskandari K; Fallaha N; Ospina LH; Javidi E; Chorfi S; Superstein R; Hamel P; Tehrani NN
    Can J Ophthalmol; 2023 Dec; 58(6):553-558. PubMed ID: 35940211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secondary 12-Month Ocular Outcomes of a Phase 1 Dosing Study of Bevacizumab for Retinopathy of Prematurity.
    Crouch ER; Kraker RT; Wallace DK; Holmes JM; Repka MX; Collinge JE; Bremer DL; Gray ME; Smith HA; Steinkuller PG;
    JAMA Ophthalmol; 2020 Jan; 138(1):14-20. PubMed ID: 31697304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial.
    Geloneck MM; Chuang AZ; Clark WL; Hunt MG; Norman AA; Packwood EA; Tawansy KA; Mintz-Hittner HA;
    JAMA Ophthalmol; 2014 Nov; 132(11):1327-33. PubMed ID: 25103848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors associated with refractive outcome in children treated with bevacizumab for retinopathy of prematurity: the importance of retinal vascularization.
    Bayramoglu SE; Sayin N
    Int Ophthalmol; 2022 Oct; 42(10):3199-3210. PubMed ID: 35579771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Refractive profile of children treated with intravitreal bevacizumab for retinopathy of prematurity.
    Pawar N; Somyashree D; Meenakshi R; Maheshwari D; Mohideen S; Sithiq Uduman M
    Indian J Ophthalmol; 2023 Jun; 71(6):2561-2568. PubMed ID: 37322680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural and refractive outcomes of intravitreal ranibizumab followed by laser photocoagulation for type 1 retinopathy of prematurity.
    Hoppe C; Holt DG; Arnold BF; Thinda S; Padmanabhan SP; Oatts JT
    J AAPOS; 2022 Dec; 26(6):305.e1-305.e6. PubMed ID: 36265750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal Bevacizumab for Zone II Retinopathy of Prematurity.
    Larrañaga-Fragoso P; Peralta J; Bravo-Ljubetic L; Pastora N; Abelairas-Gómez J
    J Pediatr Ophthalmol Strabismus; 2016 Nov; 53(6):375-382. PubMed ID: 27537247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
    Sankar MJ; Sankar J; Chandra P
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD009734. PubMed ID: 29308602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis.
    Hwang CK; Hubbard GB; Hutchinson AK; Lambert SR
    Ophthalmology; 2015 May; 122(5):1008-15. PubMed ID: 25687024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
    Sankar MJ; Sankar J; Mehta M; Bhat V; Srinivasan R
    Cochrane Database Syst Rev; 2016; 2():CD009734. PubMed ID: 26932750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined intravitreal bevacizumab injection and zone I sparing laser photocoagulation in patients with zone I retinopathy of prematurity.
    Kim J; Kim SJ; Chang YS; Park WS
    Retina; 2014 Jan; 34(1):77-82. PubMed ID: 23807184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results.
    Harder BC; Schlichtenbrede FC; von Baltz S; Jendritza W; Jendritza B; Jonas JB
    Am J Ophthalmol; 2013 Jun; 155(6):1119-1124.e1. PubMed ID: 23490192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-year refractive outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity.
    Kıran Yenice E; Petriçli İS; Kara C
    Int Ophthalmol; 2023 Jul; 43(7):2197-2202. PubMed ID: 36522564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Visual Outcomes of Laser and Anti-VEGF Treatments for Retinopathy of Prematurity.
    Gundlach BS; Kokhanov A; Altendahl M; Suh SY; Fung S; Demer J; Pineles S; Khitri M; Chu A; Tsui I
    Am J Ophthalmol; 2022 Jun; 238():86-96. PubMed ID: 34788594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LONG-TERM EFFECTS OF ANTI-VEGF MONOTHERAPY FOR RETINOPATHY OF PREMATURITY ON THE RETINAL AND REFRACTIVE DEVELOPMENT OF EYE.
    Sukgen EA; Atalay HT; Özdek Ş
    Retina; 2022 Nov; 42(11):2194-2202. PubMed ID: 35962999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Intravitreal Bevacizumab, Intravitreal Ranibizumab and Laser Photocoagulation for Treatment of Type 1 Retinopathy of Prematurity in Turkish Preterm Children.
    Kabataş EU; Kurtul BE; Altıaylık Özer P; Kabataş N
    Curr Eye Res; 2017 Jul; 42(7):1054-1058. PubMed ID: 28128986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involution patterns of retinopathy of prematurity after treatment with intravitreal bevacizumab: implications for follow-up.
    Isaac M; Tehrani N; Mireskandari K;
    Eye (Lond); 2016 Mar; 30(3):333-41. PubMed ID: 26869159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity.
    Karkhaneh R; Khodabande A; Riazi-Eafahani M; Roohipoor R; Ghassemi F; Imani M; Dastjani Farahani A; Ebrahimi Adib N; Torabi H
    Acta Ophthalmol; 2016 Sep; 94(6):e417-20. PubMed ID: 27009449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose ranibizumab as primary treatment of posterior type I retinopathy of prematurity.
    Ells AL; Wesolosky JD; Ingram AD; Mitchell PC; Platt AS
    Can J Ophthalmol; 2017 Oct; 52(5):468-474. PubMed ID: 28985806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of type 1 retinopathy of prematurity with bevacizumab versus laser.
    Isaac M; Mireskandari K; Tehrani N
    J AAPOS; 2015 Apr; 19(2):140-4. PubMed ID: 25892041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.